Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics

Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-av...

Descripción completa

Detalles Bibliográficos
Autores principales: Javorniczky, Nora Rebeka, Grishina, Olga, Hund, Inga, Pantic, Milena, Pfeifer, Dietmar, Schmoor, Claudia, Thomas, Johanna, Duyster, Justus, Becker, Heiko, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683313/
https://www.ncbi.nlm.nih.gov/pubmed/38012682
http://dx.doi.org/10.1186/s13148-023-01596-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683313/
https://www.ncbi.nlm.nih.gov/pubmed/38012682
http://dx.doi.org/10.1186/s13148-023-01596-5

Ejemplares similares